Comparative effect of angiotensin II type I receptor blockers on serum uric acid in hypertensive patients with type 2 diabetes mellitus: a retrospective observational study.

What Was Tested

Researchers studied Angiotensin II in this observational study publication.

Angiotensin II type 1 receptor blockers (ARB) are a frequently used class of antihypertensive drug.

However, there are very few clinical data comparing the effects of other ARBs on SUA level under the conditions of clinical practice.

Who Took Part

PubMed indexes the participants as middle-aged adults, both men and women.

The researchers identified hypertensive patients with type 2 DM who had been treated with monotherapy with losartan (n = 214), valsartan (n = 266), telmisartan (n = 185), candesartan (n = 458), or olmesartan (n = 192), in whom laboratory data of SUA between November 1, 2004 and July 31, 2011 were available, from the Nihon University School of Medicine's Clinical Data Warehouse (NUSM's CDW).

How the Study Was Run

The researchers used a propensity-score weighting method and a multivariate regression model to adjust for differences in the background among ARB users, and compared the SUA level.

The mean exposure of losartan was 264.7 days, valsartan 245.3 days, telmisartan 235.9 days, candesartan 248.9 days, and olmesartan 234.5 days.

What Was Measured

However, there are very few clinical data comparing the effects of other ARBs on SUA level under the conditions of clinical practice.

This study evaluated and compared the long-term effects of monotherapy with five ARBs on SUA level in Japanese hypertensive patients with type 2 diabetes mellitus (DM).

The subject headings attached to it are Angiotensin II Type 1 Receptor Blockers, Benzimidazoles, Benzoates, Biphenyl Compounds, Diabetes Mellitus, Type 2, Hypertension and Imidazoles.

What This Means in Plain Language

This is an observational study of Angiotensin II.

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2013 (Cardiovascular diabetology), a journal based in England.

More context: the Angiotensin II compound page, all human trials.